Capricor Therapeutics, Inc. (CAPR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.4000 |
| Open | 3.5000 |
| Bid | 3.4200 x 800 |
| Ask | 3.6000 x 1400 |
| Day's Range | 3.3700 - 3.5700 |
| 52 Week Range | 2.5600 - 6.2200 |
| Volume | |
| Avg. Volume | 187,206 |
| Market Cap | 84.039M |
| Beta (5Y Monthly) | 5.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8150 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- GlobeNewswire
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida. Please see additional presentation details below: H.C. Wainwright Global Inve
- GlobeNewswire
Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- -Upfront Payment of $30 Million Received in 1st Quarter Strengthens Cash Position and Extends Cash Runway- -Positive Phase 2 Results Published in The Lancet Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy- -Pivotal Phase 3 Trial Expecting to Begin Enrolling Patients this Quarter- -Pipeline Expansion Underway Using Engineered Exosome
- GlobeNewswire
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ETSAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. Management will then host a webcast and conference call a
